Dr. Moussa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12697 E 51st St
Tulsa, OK 74146Phone+1 918-505-3200Fax+1 918-505-3253
Summary
- Dr. Ali Moussa is an oncologist in Tulsa, OK and is affiliated with multiple hospitals in the area, including Hillcrest Medical Center, McAlester Regional Health Center, Saint Francis Hospital, and St. John Medical Center. He received his medical degree from American University of Beirut Faculty of Medicine and has been in practice 23 years. He also speaks multiple languages, including Arabic. He specializes in hematologic oncology and is experienced in colorectal cancer, amyloidosis, immunotherapy, hematologic oncology, and anal cancer.
Education & Training
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 1998 - 2001
Good Samaritan Hospital of MarylandResidency, Internal Medicine, 1995 - 1998
American University of Beirut Faculty of MedicineClass of 1994
American University of BeirutBS, Biology, 1986 - 1990
Certifications & Licensure
OK State Medical License 1999 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Oklahoma Super Doctors 2014
- Oklahoma Top Doctors 2013
- Oklahoma Magazine Castle Connolly, 2012-2013
- Join now to see all
Clinical Trials
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16
- Rociletinib (CO-1686) USA Expanded Access Program
Publications & Presentations
PubMed
- 60 citationsPhase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanomaAdil Daud, Harriet M. Kluger, Razelle Kurzrock, Frauke Schimmoller, Aaron Weitzman
British Journal of Cancer. 2017-01-19 - 36 citationsTreatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2Brigitte C. Widemann, Frank M. Balis, Aiman Shalabi, Matthew J. Boron, Michelle O'Brien
Journal of the National Cancer Institute. 2004-10-20
Abstracts/Posters
- Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).Adil Daud, ASCO 2013 Annual meeting, Chicago, IL, 5/30/2013
- Activity of Carbozanitinib (XL184) in Metastatic Uveal Melanoma.Moussa AH, ASCO, 1/1/2013
- Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT).Michael Gordon, ASCO 2012 annual meeting, Chicago, 6/1/2012
- Join now to see all
Lectures
- Central Nervous System Lymphoma
- Primary Mediastinal B-Cell Lymphoma
- Pure Red Cell Aplasia
- Join now to see all
Press Mentions
Health Ministry Prepared 14 Centers for Treating Coronavirus PatientsApril 6th, 2020
Professional Memberships
- Member
- Member
- Member
- Member
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
